Clinical trials
Alzheimer s Disease clinical trials
Below are recruiting alzheimer s disease clinical trials, each written for real people, not researchers. We’re tracking 595 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT05020626Recruiting
Uses brain MRI data to study Alzheimer’s disease diagnosis
This study uses brain MRI images to better understand how a protein called tau spreads in Alzheimer’s disease and related conditions. If you’re 55 or older and had an MRI close to your diagnosis, you may be eligible.
Hong Kong, ShatinAges 55 years+ - NCT06956300Recruiting
TMS to help with thinking and memory in aging
This study uses a noninvasive brain stimulation technique called TMS to see if it can slow cognitive decline in older adults who are healthy or have very early signs of Alzheimer's disease. It aims to improve memory and thinking.
Boston, MassachusettsAges 40–99 - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT05995418Recruiting
Cost and health impact study for Alzheimer's in China
This study looks at the financial and health effects of Alzheimer's disease and mild cognitive impairment (aMCI) in China. It aims to understand how the disease affects patients and families over time.
BeijingAges 40–100 - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT07233512Enrolling by invitation
Periodontal treatment for Alzheimer's disease
This trial tests whether treating gum disease can improve outcomes for people with Alzheimer's disease. If you have mild to moderate Alzheimer's and gum disease, you may be able to join.
LiègeAges Any age - NCT02649985RecruitingPhase 1/Phase 2
PET brain scan study for several brain and mood conditions
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Boston, MassachusettsAges 18–85 - NCT06170268Recruiting
Alzheimer's registry for treatment and diagnosis
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Chicago, IllinoisAges 18 years+ - NCT06918145Enrolling by invitation
LVA surgery for Alzheimer's disease
This study tests a surgery called lymphaticovenous anastomosis (LVA) as a possible treatment for Alzheimer's disease. The surgery connects tiny lymph vessels to veins to help clear waste from the brain.
Beijing, Beijing MunicipalityAges 50–85 - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT03140865Recruiting
Alzheimer’s disease research core for brain and memory testing
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
Winston-Salem, North CarolinaAges 55 years+ - NCT06338397Recruiting
Social and emotional thinking in Alzheimer's
This study looks at how Alzheimer's disease and similar conditions affect social and emotional thinking. Researchers will use brain scans and questionnaires to understand these changes better.
LilleAges 40–85 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT04804241RecruitingPhase 2
Senicapoc for early Alzheimer’s symptoms
This Phase 2 study tests whether the drug senicapoc can slow or improve symptoms in people with early Alzheimer’s disease or mild memory impairment. You would have a 50/50 chance of getting senicapoc or a placebo (inactive pill), along with regular study visits and testing.
Sacramento, CaliforniaAges 55–85 - NCT07399171RecruitingPhase 2
Testing HT-4253 to prevent Alzheimer's in APOE4 carriers
This trial tests an experimental drug called HT-4253 to see if it can prevent Alzheimer's disease in people who are at higher genetic risk (carry the APOE4 gene) and have early signs of amyloid buildup in the brain. If you qualify, you would take the drug or a placebo and be monitored over time.
Abu Dhabi, Abu Dhabi EmirateAges 50–75 - NCT07477431RecruitingPhase 2
Testing levetiracetam for those at risk of Alzheimer's
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
Toronto, OntarioAges 55–85 - NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT05151562Recruiting
Music therapy for people with early Alzheimer’s or memory loss
This trial studies whether music therapy can improve symptoms and well-being in people with early Alzheimer’s disease or mild memory problems. You may take part in music sessions and likely be screened with MRI, so the study checks safety for scans.
Baltimore, MarylandAges 18–89
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer s disease?
- Yes. Clin2 currently lists 595 recruiting alzheimer s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.